Literature DB >> 16847438

Vitamin A active metabolite, all-trans retinoic acid, induces spinal cord sensitization. II. Effects after intrathecal administration.

M Alique1, F J Lucio, J F Herrero.   

Abstract

BACKGROUND AND
PURPOSE: In our previous study (see accompanying paper) we observed that all-trans retinoic acid (ATRA) p.o. induces changes in spinal cord neuronal responses similar to those observed in inflammation-induced sensitization. In the present study we assessed the it. effects of ATRA, and its mechanisms of action. EXPERIMENTAL APPROACH: The effects of all drugs were studied after it. administration in nociceptive withdrawal reflexes using behavioural tests in awake male Wistar rats. KEY
RESULTS: The administration of ATRA in normal rats induced a dose-dependent enhancement of nociceptive responses to noxious mechanical and thermal stimulation, as well as responses to innocuous stimulation. The intensity of the responses was similar to that observed in non-treated animals after carrageenan-induced inflammation. The effect induced by ATRA was fully prevented by the previous administration of the retinoic acid receptor (RAR) pan-antagonist LE540 but not by the retinoid X receptor (RXR) pan-antagonist HX531, suggesting a selective action on spinal cord RARs. The COX inhibitor dexketoprofen and the interleukin-1 receptor antagonist IL-1ra inhibited ATRA effect. The results indicate that COX and interleukin-1 are involved in the effects of ATRA in the spinal cord, similar to that seen in inflammation. CONCLUSIONS AND IMPLICATIONS: In conclusion, ATRA induces changes in the spinal cord similar to those observed in inflammation. The sensitization-like effect induced by ATRA was mediated by RARs and associated with a modulation of COX-2 and interleukin-1 activities. ATRA might be involved in the mechanisms underlying the initiation and/or maintenance of sensitization in the spinal cord.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847438      PMCID: PMC1629404          DOI: 10.1038/sj.bjp.0706826

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  SOME NARCOTIC ANTAGONISTS IN THE BENZOMORPHAN SERIES.

Authors:  L S HARRIS; A K PIERSON
Journal:  J Pharmacol Exp Ther       Date:  1964-02       Impact factor: 4.030

Review 2.  Peripheral and central mechanisms of cutaneous hyperalgesia.

Authors:  R D Treede; R A Meyer; S N Raja; J N Campbell
Journal:  Prog Neurobiol       Date:  1992       Impact factor: 11.685

Review 3.  Cyclooxygenases 1 and 2.

Authors:  J R Vane; Y S Bakhle; R M Botting
Journal:  Annu Rev Pharmacol Toxicol       Date:  1998       Impact factor: 13.820

4.  Enhanced withdrawal responses to heat and mechanical stimuli following intraplantar injection of capsaicin in rats.

Authors:  Hart D Gilchrist; Brandon L Allard; Donald A Simone
Journal:  Pain       Date:  1996-09       Impact factor: 6.961

5.  Dynamic alterations in the cutaneous mechanoreceptive fields of dorsal horn neurons in the rat spinal cord.

Authors:  C J Woolf; A E King
Journal:  J Neurosci       Date:  1990-08       Impact factor: 6.167

6.  Alpha2-adrenoceptor stimulation transforms immune responses in neuritis and blocks neuritis-induced pain.

Authors:  E Alfonso Romero-Sandoval; Charles McCall; James C Eisenach
Journal:  J Neurosci       Date:  2005-09-28       Impact factor: 6.167

7.  Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells.

Authors:  J A Maier; T Hla; T Maciag
Journal:  J Biol Chem       Date:  1990-07-05       Impact factor: 5.157

8.  Activin A and retinoic acid synergize in cyclooxygenase-1 and thromboxane synthase induction during differentiation of J774.1 macrophages.

Authors:  R M Nüsing; S Mohr; V Ullrich
Journal:  Eur J Biochem       Date:  1995-01-15

9.  Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia.

Authors:  B Safieh-Garabedian; S Poole; A Allchorne; J Winter; C J Woolf
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

10.  Characterization of cytokine-induced hyperalgesia.

Authors:  L R Watkins; E P Wiertelak; L E Goehler; K P Smith; D Martin; S F Maier
Journal:  Brain Res       Date:  1994-08-15       Impact factor: 3.252

View more
  7 in total

1.  NCX 2057, a novel NO-releasing derivative of ferulic acid, suppresses inflammatory and nociceptive responses in in vitro and in vivo models.

Authors:  Daniela Ronchetti; Valentina Borghi; Gema Gaitan; Juan F Herrero; Francesco Impagnatiello
Journal:  Br J Pharmacol       Date:  2009-07-07       Impact factor: 8.739

2.  Retinoids activate the irritant receptor TRPV1 and produce sensory hypersensitivity.

Authors:  Shijin Yin; Jialie Luo; Aihua Qian; Junhui Du; Qing Yang; Shentai Zhou; Weihua Yu; Guangwei Du; Richard B Clark; Edgar T Walters; Susan M Carlton; Hongzhen Hu
Journal:  J Clin Invest       Date:  2013-08-08       Impact factor: 14.808

3.  LE135, a retinoid acid receptor antagonist, produces pain through direct activation of TRP channels.

Authors:  Shijin Yin; Jialie Luo; Aihua Qian; Weihua Yu; Hongzhen Hu
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

4.  All-trans retinoic acid induces COX-2 and prostaglandin E2 synthesis in SH-SY5Y human neuroblastoma cells: involvement of retinoic acid receptors and extracellular-regulated kinase 1/2.

Authors:  Matilde Alique; Juan F Herrero; Francisco Javier Lucio-Cazana
Journal:  J Neuroinflammation       Date:  2007-01-04       Impact factor: 8.322

5.  RAR/RXR and PPAR/RXR Signaling in Spinal Cord Injury.

Authors:  Sabien van Neerven; Jörg Mey
Journal:  PPAR Res       Date:  2007       Impact factor: 4.964

6.  Cambogin suppresses dextran sulphate sodium-induced colitis by enhancing Treg cell stability and function.

Authors:  Yue Lu; Na-Mi Kim; Yi-Wen Jiang; Hong Zhang; Dan Zheng; Fu-Xiang Zhu; Rui Liang; Bin Li; Hong-Xi Xu
Journal:  Br J Pharmacol       Date:  2018-02-21       Impact factor: 8.739

7.  A Novel Alternative in the Treatment of Detrusor Overactivity? In Vivo Activity of O-1602, the Newly Synthesized Agonist of GPR55 and GPR18 Cannabinoid Receptors.

Authors:  Andrzej Wróbel; Aleksandra Szopa; Anna Serefko; Ewa Poleszak
Journal:  Molecules       Date:  2020-03-18       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.